An 8-year-old neutered male Cavalier King Charles Spaniel...

Thank you for reaching out about this Cavalier King Charles Spaniel. This is a very common scenario, and your detailed workup provides excellent information for making a precise recommendation.

Based on your findings – an 8-year-old Cavalier with a Grade 3/6 left apical systolic murmur, and crucially, echocardiographic evidence of significant left atrial (LA:Ao ratio 1.8) and left ventricular enlargement (LVIDDN 2.1) – this patient falls squarely into ACVIM Stage B2 degenerative mitral valve disease.

It's important to reiterate the distinction between heart disease and heart failure. This dog has significant heart disease, but he is not yet in heart failure, as evidenced by his asymptomatic status. This distinction is critical because it dictates our treatment approach.

Given the documented hemodynamically significant remodeling (LA:Ao >1.6 and LVIDdN >1.7), the appropriate time to initiate pimobendan therapy is now, at Stage B2.

This recommendation is strongly supported by the landmark EPIC trial (Evidence of Pimobendan In Cardiomegaly). This study demonstrated that starting pimobendan in asymptomatic dogs with Stage B2 DMVD significantly delayed the onset of clinical signs of congestive heart failure and extended survival. Delaying treatment until the onset of clinical signs (Stage C) means missing a critical opportunity to improve the patient's quality and quantity of life.

For this patient, I would recommend initiating pimobendan at a dose of 0.25–0.3 mg/kg PO Every 12 hours. It is crucial to ensure the medication is given on an empty stomach, ideally one hour before food, as food can significantly reduce its absorption.

While he is asymptomatic, I always advise owners to monitor their dog's sleeping respiratory rate (SRR) at home. A normal sleeping respiratory rate is typically less than 30 breaths per minute. This is the single most useful early indicator of impending heart failure, and empowering owners with this tool can be life-saving.

We would continue to monitor this patient with an echocardiogram every 6 months to a year, or sooner if any clinical signs develop. There is no indication for furosemide at this stage, as there are no signs of congestive heart failure, and its use would only activate the RAAS and risk dehydration without benefit.

Let me know if you have any further questions or if you'd like to discuss the nuances of the EPIC trial findings.